Establishment of Prevention and Treatment for Development of Atherosclerosis by regulation of Lipocalin-Type Prostaglandin D Synthase

点击翻译按钮获取中文摘要

Lipocalin-type prostaglandin (PG) D synthase (L-PGDS), which is responsible for the biosynthesis of PGD2, has recently been found to be present in the atherosclerotic plaque of the human coronary artery and also to be detectable in human serum. L-PGDS is one of the enzymes that catalyze PGD2 synthesis, and so we speculate that PGD2 synthesis mediated by L-PGDS is related to pathogenesis of atherosclerosis. Considering the roles of L-PGDS in the pathophysiology of coronary artery disease, it is suggested that L-PGDS generation in the atherosclerotic plaques has an anti-atherogenic effect. Furthermore, we observed the immunoreactivity and mRNA expression of L-PGDS to confirm that L-PGDS was definitely localized and generated in atherosclerotic plaques, especially in these in the human and monkey coronary artery.The major findings are that serum L-PGDS level was elevated in patients with coronary artery disease and that the level increased in association with the number of affected vessels (Teruo inoue, Yutaka Eguchi, Tetsuya Matsumoto, Yoshihiro Urade et al. Lipocalin-type prostaglandin D synthase is a powerful biomarker for severity of coronary artery disease, submitted). The serum L-PGDS level may be suitable to evaluate the severity of coronary artery disease. It is concluded that the measurement of serum L-PGDS can be a strategy for screening of coronary artery disease prior to coronary angiography.